Manager × security

Artal Group S.A. LXRX holdings history

LEXICON PHARMACEUTICALS INC · CUSIP 528872302 · CIK 1053906

Some filings reported values in thousands; those figures were scaled ×1000 to dollars.
This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Artal Group S.A. reported 175.16M LXRX (shares), valued at $420.37M, or 45.15% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
45.15%
Shares
175.16M
175,156,062
Reported value
$420.37M
USD

Shares increased 13.20%; reported value increased 74.15%, and weight changed +21.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202645.15%175,156,062SEC filing ↗Filed Aug 13, 2026
Q1 202623.89%154,734,327SEC filing ↗Filed May 14, 2026
Q4 202521.91%136,180,481SEC filing ↗Filed Feb 12, 2026
Q3 202524.25%136,180,481SEC filing ↗Filed Nov 12, 2025
Q2 202513.91%136,180,481SEC filing ↗Filed Aug 13, 2025
Q1 20257.08%136,180,481SEC filing ↗Filed May 14, 2025
Q4 20248.59%136,180,481SEC filing ↗Filed Feb 14, 2025
Q3 20248.98%136,180,481SEC filing ↗Filed Nov 13, 2024
Q2 20247.55%175,099,384SEC filing ↗Filed Aug 14, 2024
Q1 20247.27%117,553,284SEC filing ↗Filed May 17, 2024Amended
Q4 20236.13%117,553,284SEC filing ↗Filed Feb 9, 2024
Q3 20235.59%117,553,284SEC filing ↗Filed Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20235.59%117,553,284$128.13MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 13, 2023
Q4 20236.13%117,553,284$179.86MShares unchanged; reported value increased 40.37%, and weight changed +0.54 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 9, 2024
Q1 20247.27%117,553,284$282.13MShares unchanged; reported value increased 56.86%, and weight changed +1.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 17, 2024
Q2 20247.55%175,099,384$294.17MShares increased 48.95%; reported value increased 4.27%, and weight changed +0.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20248.98%136,180,481$213.80MShares decreased 22.23%; reported value decreased 27.32%, and weight changed +1.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 20248.59%136,180,481$100.77MShares unchanged; reported value decreased 52.87%, and weight changed -0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20257.08%136,180,481$62.64MShares unchanged; reported value decreased 37.84%, and weight changed -1.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 202513.91%136,180,481$129.37MShares unchanged; reported value increased 106.52%, and weight changed +6.83 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2025
Q3 202524.25%136,180,481$183.84MShares unchanged; reported value increased 42.11%, and weight changed +10.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 12, 2025
Q4 202521.91%136,180,481$156.61MShares unchanged; reported value decreased 14.81%, and weight changed -2.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2026
Q1 202623.89%154,734,327$241.39MShares increased 13.62%; reported value increased 54.13%, and weight changed +1.98 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2026
Q2 202645.15%175,156,062$420.37MShares increased 13.20%; reported value increased 74.15%, and weight changed +21.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
Artal Group S.A. · LEXICON PHARMACEUTICALS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1053906","quarter":"2026Q2","cusip":"528872302"}

get_institutional_manager_history
{"cik":"1053906","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.